New trial
Phase 1/2 Study of Intravesical Sacituzumab Tirumotecan in Intermediate-risk NMIBC
- Trial ID
- NCT06637423 on ClinicalTrials.gov
- Cancer type
- Bladder Cancer
- Location
- 5 Locations
- Published in
- New in Oncology - May 21, 2025
Merck is launching an open-label study to assess the safety, tolerability, and optimal dosing of intravesically administered Sacituzumab Tirumotecan in participants with intermediate-risk, low-grade, recurrent NMIBC. Participants will receive treatment for 6 weeks to determine the ideal dose for future trials.
More in bladder and urothelial cancer
-
Trial result · Oct 15, 2026 · NCT04179162
GemBCG (intravesical gemcitabine + BCG immunostimulation) delivers 96% 6‑mo CR in BCG-exposed high‑grade NMIBC -
Trial result · Oct 15, 2026 · NCT02773849
TAR-200 (intravesical gemcitabine device) vs nadofaragene firadenovec: no statistically significant CR durability difference detected through 24 months in BCG-unresponsive CIS -
New trial · Oct 15, 2026 · NCT07827612
Phase 2 FORAY tests selective FGFR3 inhibition with vepugratinib in low-grade bladder and upper tract urothelial tumors -
New trial · Oct 8, 2026 · NCT07815665
Phase 2/3 Ivonescimab PD-1×VEGF bispecific antibody plus enfortumab vedotin Nectin-4 ADC in la/mUC -
New trial · Oct 8, 2026 · NCT07822373
Phase 2 enfortumab vedotin Nectin-4 ADC (MMAE tubulin payload) plus pembrolizumab PD-1 antibody